Docetaxel Injection, Solution
Product Images NDC 0409-0366
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 0409-0366). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Docetaxel 02)
The text describes a figure labeled as "Figure 1-TAX316 Disease Free Survival K-M Curve". It appears to be a graph showing the disease-free survival rates over time (in months) with percentages indicated on the Y-axis and time indicated on the X-axis. However, the graph seems to be corrupted with random symbols and characters, making it difficult to interpret.*
Figure 2 (Docetaxel 03)
This is a description of a figure labeled as "Figure 2 - TAX316 Overall Survival K-M Curve". The graph shows the overall survival of a group of individuals over time, with the x-axis displaying survival time in months and the y-axis displaying the probability of survival. Specific time intervals of 6 months are marked on the x-axis up to 66 months. No further information is available to provide additional context or interpretation of this graph.*
Figure 3 (Docetaxel 04)
The text describes a chart showing the survival probability over time for two different treatments for TAX317. One treatment involves Docetaxel at a dose of 75 mg/m?, while the other treatment involves Best Supportive Care. The chart plots survival probability on the y-axis and time in months on the x-axis. The chart shows cumulative probabilities for both treatments at various time points up to 15 months.*
Figure 4 (Docetaxel 05)
Figure 5 (Docetaxel 06)
Figure 6 (Docetaxel 07)
The text represents a figure titled "Gastric Cancer Study (TAX325) Time to Progression K-M Curve". The figure contains a graph showing the probability of time to progression for gastric cancer patients over a period of several months. Unfortunately, due to the lack of context, it is not possible to provide more information on the data and its significance.*
Figure 7 (Docetaxel 08)
This is a Survival K-M Curve for Gastric Cancer Study (TAX325). It shows the survival rate over time in months. The x-axis shows the survival time in months and the y-axis shows the survival rate in percentage. The curve shows a steady decline in survival rate over time. The data is presented in a graph format.*
Figure 8 (Docetaxel 09)
The image shows a graph, specifically a Kaplan-Meier curve for the TAX323 study. The x-axis shows the progression-free survival time in months, while the y-axis shows the PFS probability percentage. The curve represents the likelihood of patients in the study remaining progression-free over time. The data points on the curve indicate the probability at specific time intervals.*
Figure 9 (Docetaxel 10)
Figure 10 (Docetaxel 11)
Logo (Docetaxel 12)
Logo (Docetaxel 12a)
Principal Display Panel (1 mL Vial Label)
Docetaxel Injection is a single-dose vial with a concentration of 20 mg/mL and NDC 0409-0366-01. It is ready to be added to an infusion solution for intravenous use. Any unused portion must be discarded. Prior to preparation, the concentration should be checked as per the package insert's instructions. The product is manufactured by Hospira, Inc., located in Lake Forest, IL60045 USA. Other details are not available.*
Principal Display Panel (1 mL Vial Carton)
Principal Display Panel (4 mL Vial Label)
This is a product description for 4 mL multiple-dose vial of Docetaxel Injection, USP, containing 80 mg/4 mL. The vial is sterile and has a National Drug Code (NDC) number of 0409-0367-01. It is ready to be added to an infusion solution for intravenous use only. The user must check the concentration before preparing the solution. The package insert, with complete instructions, is available for the 20 mg/mL concentration. The lot number for this product is ZHL190071.*
Principal Display Panel (4 mL Vial Carton)
This is a description of a medication, specifically a multiple-dose vial of Docetaxel Injection, with a concentration of 80 mg/4 mL (20 mg/mL). It is ready to be added to an infusion solution for administration. The medication contains Dactol and citric acid monohydrate and is stored between 2°C and 25°C. The medication is a cytotoxic agent and should be handled with caution. The package insert contains complete instructions and dosage information. The medication is distributed by Hospira, Inc.*
Principal Display Panel (8 mL Vial Label)
Principal Display Panel (8 mL Vial Carton)
This is a product description for an injection solution called Docetaxel in the Hospira product line. It is a 160mg/8mL (20mg/mL) ready to add to infusion solution. This description includes warnings to keep it away from children, directions to retain in original package, and proper storage between 2-8°C (36-46°F). Additionally, there is a cautionary note stating that it is not to be used for agents. Please see the package insert for complete instructions on usage, dosage, and handling.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.